

| | |
|--|--|
| | |
| | |

medical

07/28/2020

Diagnostic requirements (#3) updated to require both conditions: advanced bone age and GnRH stimulation test or pubertal hormone levels; removed ruled out diagnoses; removed list of secondary puberty signs and symptoms (redundancy); removed baseline weight; specified baseline LH hormones; Added requirement for discontinuation of treatment in reauth; added prescriber requirement.

References:

1. Triptodur [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2018.
2. ClinicalTrials.gov Identifier: NCT00564850. Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty (DECAPUB). Available at: <https://clinicaltrials.gov/ct2/show/NCT00564850>.
3. Eksioglu AS, et al. Value of pelvic sonography in the diagnosis of various forms of precocious puberty in girls. J Clin Ultrasound. 2013 Feb;41(2):84-93.
- 4.